^
BIOMARKER:

TP53 mutation

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Entrez ID:
TP53 mutation
Hairy Cell Leukemia
rituximab + cladribine
Resistant: C3 – Early Trials
Blood Adv - 3 weeks
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
TP53 mutation
CLL
venetoclax
Sensitive: A1 - Approval
TP53 mutation
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
TP53 mutation
CLL
acalabrutinib
Sensitive: A1 - Approval
TP53 mutation
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
TP53 mutation
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
venetoclax + rituximab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
zanubrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
ofatumumab
Resistant: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
idelalisib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
ofatumumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
CLL
lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab + nivolumab + ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
nivolumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
duvelisib
Sensitive: A2 - Guideline
TP53 mutation
CLL
obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
pembrolizumab
Sensitive: A2 - Guideline
TP53 mutation
MDS
APR-246
Sensitive: B - Late Trials
TP53 mutation
AML
APR-246
Sensitive: B - Late Trials
TP53 mutation
AML
venetoclax
Resistant: B - Late Trials
TP53 mutation
Hormone Receptor Positive Breast Cancer
capecitabine
Resistant: B - Late Trials
TP53 mutation
CLL
chlorambucil
Resistant: B - Late Trials
TP53 mutation
NSCLC
Immunotherapy
Sensitive: B - Late Trials
TP53 mutation
Breast Cancer
tamoxifen
Resistant: B - Late Trials
TP53 mutation
CLL
ibrutinib + ublituximab
Sensitive: B - Late Trials
TP53 mutation
HER2 Negative Breast Cancer
talazoparib
Resistant: B - Late Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
venetoclax
Sensitive: C1 - Off-label
TP53 mutation
T Acute Lymphoblastic Leukemia
venetoclax
Sensitive: C1 - Off-label
TP53 mutation
MDS
CB-839
Sensitive: C2 – Inclusion Criteria
TP53 mutation
Ovarian Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
TP53 mutation
NSCLC
pembrolizumab
Sensitive: C2 – Inclusion Criteria
TP53 mutation
CLL
venetoclax + obinutuzumab + acalabrutinib
Sensitive: C2 – Inclusion Criteria
TP53 mutation
MDS
decitabine
Sensitive: C2 – Inclusion Criteria
TP53 mutation
AML
decitabine
Sensitive: C2 – Inclusion Criteria
TP53 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
TP53 mutation
Mantle Cell Lymphoma
rituximab + ibrutinib
Sensitive: C2 – Inclusion Criteria
TP53 mutation
SCCHN
AZD1775
Sensitive: C2 – Inclusion Criteria
TP53 mutation
Ovarian Cancer
ADX-1612
Sensitive: C2 – Inclusion Criteria
TP53 mutation
CRC
cetuximab
Sensitive: C2 – Inclusion Criteria
TP53 mutation
Urothelial Cancer
LY3143921
Sensitive: C2 – Inclusion Criteria
TP53 mutation
GastroEsophageal Cancer
Immunotherapy
Resistant: C3 – Early Trials
TP53 mutation
Pancreatic Cancer
gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
TP53 mutation
AML
cytarabine/daunorubicin liposomal formulation
Resistant: C3 – Early Trials
TP53 mutation
AML
venetoclax + RO5503781
Sensitive: C3 – Early Trials
TP53 mutation
AML
cytarabine
Resistant: C3 – Early Trials
TP53 mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
TP53 mutation
Mantle Cell Lymphoma
rituximab + ibrutinib + lenalidomide
Sensitive: C3 – Early Trials
TP53 mutation
NHL
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
TP53 mutation
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
TP53 mutation
CRC
bevacizumab + cetuximab
Sensitive: C3 – Early Trials
TP53 mutation
AML
venetoclax + MLN4924
Sensitive: C3 – Early Trials
TP53 mutation
CLL
ICP-022
Sensitive: C3 – Early Trials
TP53 mutation
AML
nivolumab
Sensitive: C3 – Early Trials
TP53 mutation
LUAD
Immunotherapy
Sensitive: C3 – Early Trials
TP53 mutation
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
TP53 mutation
Small Lymphocytic Lymphoma
LOXO-305
Sensitive: C3 – Early Trials
TP53 mutation
CLL
LOXO-305
Sensitive: C3 – Early Trials
TP53 mutation
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
TP53 mutation
NSCLC
atezolizumab
Resistant: C3 – Early Trials
TP53 mutation
Neuroendocrine Tumor
pazopanib
Sensitive: C3 – Early Trials
TP53 mutation
AML
cytarabine
Resistant: C3 – Early Trials
TP53 mutation
SCCHN
PD1 inhibitor
Sensitive: C3 – Early Trials
TP53 mutation
AML
cytarabine + idarubicin hydrochloride
Sensitive: C3 – Early Trials
TP53 mutation
CLL
RP6530
Sensitive: C3 – Early Trials
TP53 mutation
AML
Hu5F9-G4
Sensitive: C3 – Early Trials
TP53 mutation
Lymphoma
CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy
Sensitive: C3 – Early Trials
TP53 mutation
AML
CFI-400945
Sensitive: C3 – Early Trials